Read by QxMD icon Read

Derek yellon

Heerajnarain Bulluck, Stefania Rosmini, Amna Abdel-Gadir, Anish N Bhuva, Thomas A Treibel, Marianna Fontana, Esther Gonzalez-Lopez, Manish Ramlall, Ashraf Hamarneh, Alex Sirker, Anna S Herrey, Charlotte Manisty, Derek M Yellon, James C Moon, Derek J Hausenloy
PURPOSE: To investigate the performance of T1 and T2 mapping to detect intramyocardial hemorrhage (IMH) in ST-segment elevation myocardial infarction (STEMI) patients treated by primary percutaneous coronary intervention (PPCI). MATERIALS AND METHODS: Fifty STEMI patients were prospectively recruited between August 2013 and July 2014 following informed consent. Forty-eight patients completed a 1.5T cardiac magnetic resonance imaging (MRI) with native T1 , T2 , and T2* maps at 4 ± 2 days...
February 15, 2017: Journal of Magnetic Resonance Imaging: JMRI
John V McGowan, Robin Chung, Angshuman Maulik, Izabela Piotrowska, J Malcolm Walker, Derek M Yellon
Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer. Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The basic mechanisms of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase 2 as well as other indirect pathways. Cardioprotective treatments are few and those that have been examined include renin angiotensin system blockade, beta blockers, or the iron chelator dexrazoxane...
February 9, 2017: Cardiovascular Drugs and Therapy
Heerajnarain Bulluck, Jennifer Nicholas, Gabriele Crimi, Steven K White, Andrew J Ludman, Silvia Pica, Claudia Raineri, Hector A Cabrera-Fuentes, Derek Yellon, Jose Rodriguez-Palomares, David Garcia-Dorado, Derek J Hausenloy
OBJECTIVE: Clinical studies using serum cardiac biomarkers to investigate a circadian variation in acute myocardial infarct (MI) size in ST-segment elevation myocardial infarction (STEMI) patients reperfused by primary percutaneous coronary intervention (PPCI) have produced mixed results. We aimed to investigate this phenomenon using acute MI size measured by cardiovascular magnetic resonance (CMR). METHODS: Patient-level data was obtained from 4 randomized controlled trials investigating the MI-limiting effects of cardioprotective therapies in this pooled analysis...
March 1, 2017: International Journal of Cardiology
Daniel I Bromage, Jack M J Pickard, Xavier Rossello, Oliver J Ziff, Niall Burke, Derek M Yellon, Sean M Davidson
AIMS: The potential of remote ischaemic conditioning (RIC) to ameliorate myocardial ischaemia-reperfusion injury (IRI) remains controversial. We aimed to analyse the pre-clinical evidence base to ascertain the overall effect and variability of RIC in animal in vivo models of myocardial IRI. Furthermore, we aimed to investigate the impact of different study protocols on the protective utility of RIC in animal models and identify gaps in our understanding of this promising therapeutic strategy...
October 23, 2016: Cardiovascular Research
Heerajnarain Bulluck, Stefania Rosmini, Amna Abdel-Gadir, Steven K White, Anish N Bhuva, Thomas A Treibel, Marianna Fontana, Manish Ramlall, Ashraf Hamarneh, Alex Sirker, Anna S Herrey, Charlotte Manisty, Derek M Yellon, Peter Kellman, James C Moon, Derek J Hausenloy
BACKGROUND: The presence of intramyocardial hemorrhage (IMH) in ST-segment-elevation myocardial infarction patients reperfused by primary percutaneous coronary intervention has been associated with residual myocardial iron at follow-up, and its impact on adverse left ventricular (LV) remodeling is incompletely understood and is investigated here. METHODS AND RESULTS: Forty-eight ST-segment-elevation myocardial infarction patients underwent cardiovascular magnetic resonance at 4±2 days post primary percutaneous coronary intervention, of whom 40 had a follow-up scan at 5±2 months...
October 2016: Circulation. Cardiovascular Imaging
Xavier Rossello, Derek M Yellon
The EMPA-REG OUTCOME and the LEADER trials have revealed a new era in the management of type 2 diabetes. The SGLT2 inhibitor empagliflozin demonstrated a lower rate of the primary composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke compared to placebo. Liraglutide, a GLP-1 analogue, succeeded to demonstrate reduction on a composite outcome including first occurrence of cardiovascular death, nonfatal myocardial infarction or non-fatal stroke. These two medications act through different mechanisms and has consequently shown different patterns of cardiovascular benefit...
February 1, 2017: International Journal of Cardiology
Sean M Davidson, Kaloyan Takov, Derek M Yellon
Most, if not all, cells of the cardiovascular system secrete small, lipid bilayer vesicles called exosomes. Despite technical challenges in their purification and analysis, exosomes from various sources have been shown to be powerfully cardioprotective. Indeed, it is possible that much of the so-called "paracrine" benefit in cardiovascular function obtained by stem cell therapy can be replicated by the injection of exosomes produced by stem cells. However, exosomes purified from plasma appear to be just as capable of activating cardioprotective pathways...
October 29, 2016: Cardiovascular Drugs and Therapy
Derek J Hausenloy, Jose A Barrabes, Hans Erik Bøtker, Sean M Davidson, Fabio Di Lisa, James Downey, Thomas Engstrom, Péter Ferdinandy, Hector A Carbrera-Fuentes, Gerd Heusch, Borja Ibanez, Efstathios K Iliodromitis, Javier Inserte, Robert Jennings, Neena Kalia, Rajesh Kharbanda, Sandrine Lecour, Michael Marber, Tetsuji Miura, Michel Ovize, Miguel A Perez-Pinzon, Hans Michael Piper, Karin Przyklenk, Michael Rahbek Schmidt, Andrew Redington, Marisol Ruiz-Meana, Gemma Vilahur, Jakob Vinten-Johansen, Derek M Yellon, David Garcia-Dorado
To commemorate the auspicious occasion of the 30th anniversary of IPC, leading pioneers in the field of cardioprotection gathered in Barcelona in May 2016 to review and discuss the history of IPC, its evolution to IPost and RIC, myocardial reperfusion injury as a therapeutic target, and future targets and strategies for cardioprotection. This article provides an overview of the major topics discussed at this special meeting and underscores the huge importance and impact, the discovery of IPC has made in the field of cardiovascular research...
November 2016: Basic Research in Cardiology
Hector A Cabrera-Fuentes, Julian Aragones, Jürgen Bernhagen, Andreas Boening, William A Boisvert, Hans E Bøtker, Heerajnarain Bulluck, Stuart Cook, Fabio Di Lisa, Felix B Engel, Bernd Engelmann, Fulvia Ferrazzi, Péter Ferdinandy, Alan Fong, Ingrid Fleming, Erich Gnaiger, Sauri Hernández-Reséndiz, Siavash Beikoghli Kalkhoran, Moo Hyun Kim, Sandrine Lecour, Elisa A Liehn, Michael S Marber, Manuel Mayr, Tetsuji Miura, Sang-Bing Ong, Karlheinz Peter, Daniel Sedding, Manvendra K Singh, M Saadeh Suleiman, Hans J Schnittler, Rainer Schulz, Winston Shim, Daniel Tello, Carl-Wilhelm Vogel, Malcolm Walker, Qilong Oscar Yang Li, Derek M Yellon, Derek J Hausenloy, Klaus T Preissner
In this meeting report, particularly addressing the topic of protection of the cardiovascular system from ischemia/reperfusion injury, highlights are presented that relate to conditioning strategies of the heart with respect to molecular mechanisms and outcome in patients' cohorts, the influence of co-morbidities and medications, as well as the contribution of innate immune reactions in cardioprotection. Moreover, developmental or systems biology approaches bear great potential in systematically uncovering unexpected components involved in ischemia-reperfusion injury or heart regeneration...
November 2016: Basic Research in Cardiology
Xavier Rossello, Derek M Yellon
No abstract text is available yet for this article.
August 23, 2016: Circulation
Heerajnarain Bulluck, Stefania Rosmini, Amna Abdel-Gadir, Steven K White, Anish N Bhuva, Thomas A Treibel, Marianna Fontana, Esther Gonzalez-Lopez, Patricia Reant, Manish Ramlall, Ashraf Hamarneh, Alex Sirker, Anna S Herrey, Charlotte Manisty, Derek M Yellon, Peter Kellman, James C Moon, Derek J Hausenloy
BACKGROUND: Whether the remote myocardium of reperfused ST-segment elevation myocardial infarction (STEMI) patients plays a part in adverse left ventricular (LV) remodeling remains unclear. We aimed to use automated extracellular volume fraction (ECV) mapping to investigate whether changes in the ECV of the remote (ECVR emote) and infarcted myocardium (ECVI nfarct) impacted LV remodeling. METHODS AND RESULTS: Forty-eight of 50 prospectively recruited reperfused STEMI patients completed a cardiovascular magnetic resonance at 4±2 days and 40 had a follow-up scan at 5±2 months...
July 2016: Journal of the American Heart Association
Xavier Rossello, Derek M Yellon
The failure to translate novel cardioprotective therapies tested in pre-clinical studies into the clinical setting for patient benefit can be attributed to a number of factors at different stages of the research process. This review focuses on the evidences and the gaps with regard to the translational journey of cardioprotective interventions. Gaps are classified into 3 main groups: 1) those related to pre-clinical studies, 2) those associated with the validation of infarct size as a good surrogate and 3) those based on design and interpretation of randomized clinical trials on cardioprotection...
October 1, 2016: International Journal of Cardiology
Jack M J Pickard, Sean M Davidson, Derek J Hausenloy, Derek M Yellon
The cardioprotection afforded by remote ischaemic conditioning (RIC) is mediated via a complex mechanism involving sensory afferent nerves, the vagus nerve, and release of a humoral blood-borne factor. However, it is unknown whether release of the protective factor depends on vagal activation or occurs independently. This study aimed to evaluate the co-dependence of the neural and humoral pathways of RIC, focussing on the vagus nerve and intrinsic cardiac ganglia. In the first study, anesthetised rats received bilateral cervical vagotomy or sham-surgery immediately prior to RIC (4 × 5 min limb ischemia-reperfusion) or sham-RIC...
July 2016: Basic Research in Cardiology
Xavier Rossello, Niall Burke, Christian Stoppe, Jurgen Bernhagen, Sean M Davidson, Derek M Yellon
PURPOSE: Evidence suggests a two-pronged role of endogenous macrophage migration inhibitory factor (MIF) release in ischemia/reperfusion injury. We aimed to assess whether its exogenous administration confers cardioprotection. METHODS: Male C57/BL6 mice were randomly allocated to receive recombinant mouse MIF (rMIF) at physiological (ng/mL) concentrations in a dose-response fashion before or after a protocol of 35 min of ischemia and 2 h of reperfusion in an isolated Langendorff-perfused model with infarct size as endpoint...
October 2016: Cardiovascular Drugs and Therapy
Derek J Hausenloy, Hans Erik Botker, Thomas Engstrom, David Erlinge, Gerd Heusch, Borja Ibanez, Robert A Kloner, Michel Ovize, Derek M Yellon, David Garcia-Dorado
No abstract text is available yet for this article.
April 26, 2016: European Heart Journal
Heerajnarain Bulluck, Steven K White, Georg M Fröhlich, Steven G Casson, Celia O'Meara, Ayla Newton, Jennifer Nicholas, Peter Weale, Simon M Y Wan, Alex Sirker, James C Moon, Derek M Yellon, Ashley Groves, Leon Menezes, Derek J Hausenloy
BACKGROUND: Hybrid positron emission tomography and magnetic resonance allows the advantages of magnetic resonance in tissue characterizing the myocardium to be combined with the unique metabolic insights of positron emission tomography. We hypothesized that the area of reduced myocardial glucose uptake would closely match the area at risk delineated by T2 mapping in ST-segment-elevation myocardial infarction patients. METHODS AND RESULTS: Hybrid positron emission tomography and magnetic resonance using (18)F-fluorodeoxyglucose (FDG) for glucose uptake was performed in 21 ST-segment-elevation myocardial infarction patients at a median of 5 days...
March 2016: Circulation. Cardiovascular Imaging
Heerajnarain Bulluck, Robert L Yellon, Derek M Yellon
Morbidity in patients presenting with acute ST-segment elevation myocardial infarction remains significant despite prompt reperfusion by primary percutaneous coronary intervention. This has been partly attributed to "myocardial reperfusion injury" whereby the process of restoring coronary blood flow paradoxically induces myocardial injury and cardiomyocyte death, mitigating the full beneficial effects of reperfusion. A large number of cardioprotective therapies to reduce myocardial infarct size have been investigated in preclinical and small proof-of-concept clinical studies with mixed results...
June 2016: Minerva Cardioangiologica
Derek J Hausenloy, Derek M Yellon
The 30-year anniversary of the discovery of 'ischaemic preconditioning' is in 2016. This endogenous phenomenon can paradoxically protect the heart from acute myocardial infarction by subjecting it to one or more brief cycles of ischaemia and reperfusion. Apart from complete reperfusion, this method is the most powerful intervention known for reducing infarct size. The concept of ischaemic preconditioning has evolved into 'ischaemic conditioning', a term that encompasses a number of related endogenous cardioprotective strategies, applied either directly to the heart (ischaemic preconditioning or postconditioning) or from afar, for example a limb (remote ischaemic preconditioning, perconditioning, or postconditioning)...
April 2016: Nature Reviews. Cardiology
Robin Chung, Angshuman Maulik, Ashraf Hamarneh, Daniel Hochhauser, Derek J Hausenloy, J Malcolm Walker, Derek M Yellon
Cancer survival continues to improve, and thus cardiovascular consequences of chemotherapy are increasingly important determinants of long-term morbidity and mortality. Conventional strategies to protect the heart from chemotherapy have important hemodynamic or myelosuppressive side effects. Remote ischemic conditioning (RIC) using intermittent limb ischemia-reperfusion reduces myocardial injury in the setting of percutaneous coronary intervention. Anthracycline cardiotoxicity and ischemia-reperfusion injury share common biochemical pathways in cardiomyocytes...
February 2016: Clinical Cardiology
Michael V Cohen, Xi-Ming Yang, James White, Derek M Yellon, Robert M Bell, James M Downey
In animal models platelet P2Y12 receptor antagonists put the heart into a protected state, not as a result of suppressed thrombosis but rather through protective signaling, similar to that for ischemic postconditioning. While both ischemic postconditioning and the P2Y12 blocker cangrelor protect blood-perfused hearts, only the former protects buffer-perfused hearts indicating that the blocker requires a blood-borne constituent or factor to protect. We used an anti-platelet antibody to make thrombocytopenic rats to test if that factor resides within the platelet...
April 2016: Cardiovascular Drugs and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"